PEQUOD: PErfusion QUality ODds

Sponsor
IRCCS Policlinico S. Donato (Other)
Overall Status
Recruiting
CT.gov ID
NCT06019546
Collaborator
(none)
400
1
11.2
35.6

Study Details

Study Description

Brief Summary

Cardiac surgery-associated acute kidney injury (CSA-AKI) is a frequent complication after cardiac operations with cardiopulmonary bypass (CPB) use. Its frequency varies depending on the severity grade. There are different "static" predictive scores for the CSA-AKI based on the patient and surgery-associated parameters.

Recently, in our Institution was developed a predictive algorithm for CSA-AKI that starts with a static model and then integrated with 7 CPB-associated parameters: HCT, DO2, time of exposure to a critical DO2, systemic pressure, CPB duration time, lactate value, transfusion of red blood cells (RBC), that together build a dynamic perfusion risk (DPR) associated to the CPB. Combining the static and dynamic models produces the Multifactorial Dynamic Perfusion Index (MDPI).

The present study validates MDPI in a new prospective series of patients undergoing cardiac surgery with CPB.

Condition or Disease Intervention/Treatment Phase
  • Other: PEQUOD

Detailed Description

Cardiac surgery-associated acute kidney injury (CSA-AKI) is a frequent complication after cardiac operations with cardiopulmonary bypass (CPB) use. Its frequency varies depending on the severity grade which for the present study follows the AKIN criteria.

There are different predictive scores for the CSA-AKI based on the patient and surgery-associated parameters. These models could be defined as "static".

It's known that a number of CPB-associated parameters could influence CSA-AKI, as well. These include hematocrit (HCT), oxygen delivery (DO2), time of exposure to a critical DO2, and perfusion pressure. These parameters, taken separately, are associated with CSA-AKI development.

Recently, our Institution has developed a predictive algorithm for CSA-AKI that starts with a static model and then integrated with 7 CPB-associated parameters: HCT, DO2, time of exposure to a critical DO2, systemic pressure, CPB duration time, lactate value, transfusion of red blood cells (RBC), that together build a dynamic perfusion risk (DPR) associated to the CPB. Combining the static and dynamic models produces the Multifactorial Dynamic Perfusion Index (MDPI).

MDPI has higher discrimination power when compared to the static scores, in the original series and in the internal validation with the Bootstrap technique.

The present study validates MDPI in a new prospective series of patients undergoing cardiac surgery with CPB. An enrollment of 400 patients is anticipated with a stopping rule for efficacy at interim analysis (for primary endpoint) at 50% enrollment (200 patients) if the c-statistics for any stage of CSA-AKI reaches at least 0.75. Futility is defined as an AUC of 0.6 or lower.

Study Design

Study Type:
Observational
Anticipated Enrollment :
400 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Perfusion Quality Odds
Actual Study Start Date :
Jan 23, 2023
Anticipated Primary Completion Date :
Dec 31, 2023
Anticipated Study Completion Date :
Dec 31, 2023

Arms and Interventions

Arm Intervention/Treatment
PEQUOD

Patients undergoing cardiac surgery with cardiopulmonary bypass whose parameters of interest will be registered during cardiopulmonary bypass by the Livanova BE-CAPTA monitor.

Other: PEQUOD
During cardiopulmonary bypass registration of the parameters of interest by the Livanova BE-CAPTA monitor. After surgery, registration of creatinine values up to 48 postoperative hours.

Outcome Measures

Primary Outcome Measures

  1. Acute kidney injury [First 48 postoperative hours]

    Occurence of any stage acute kidney injury as defined by the AKIN criteria

Secondary Outcome Measures

  1. Respiratory insufficiency [First 48 postoperative hours]

    P/F ratio > 200 with radiographic evidence of pulmonary distress, if compared to the baseline by an independent radiologist

  2. Low cardiac output [First 48 postoperative hours]

    Use of inotrope drugs for more than 48 hours and/or mechanical support

  3. Major morbidity [First 48 postoperative hours]

    As defined by STS criteria as one or more of the following items: AKI stage 2, stroke, mechanical ventilation duration > 48 hours, sepsis, surgical re-exploration

  4. Prolonged ICU stay [First 4 postoperative days]

    ICu stay duration > 4 days

  5. Mortality [30 days after surgery]

    Dead or alive status

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • patients undergoing cardiac surgery with cardiopulmonary bypass

  • age of 18 years and higher

  • willingness to participate and sign the informed consent

Exclusion Criteria:
  • patients requiring preoperative dialysis

Contacts and Locations

Locations

Site City State Country Postal Code
1 IRCCS Policlinico San Donato San Donato Milanese MI Italy 20097

Sponsors and Collaborators

  • IRCCS Policlinico S. Donato

Investigators

  • Principal Investigator: Marco Ranucci, MD, IRCCS Policlinico S. Donato

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Marco Ranucci, Director of the Cardiovascular Anesthesia and Intensive Care Department, IRCCS Policlinico S. Donato
ClinicalTrials.gov Identifier:
NCT06019546
Other Study ID Numbers:
  • PEQUOD
First Posted:
Aug 31, 2023
Last Update Posted:
Aug 31, 2023
Last Verified:
Aug 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Marco Ranucci, Director of the Cardiovascular Anesthesia and Intensive Care Department, IRCCS Policlinico S. Donato
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 31, 2023